Literature DB >> 12727133

Olanzapine's effects to reduce fear and anxiety and enhance social interactions coincide with increased progestin concentrations of ovariectomized rats.

Cheryl A Frye1, Angela M Seliga.   

Abstract

Administration of olanzapine, an antipsychotic drug, can dose-dependently increase the levels of progesterone's metabolite, 5 alpha-pregnane-3 alpha-ol-20-one (3 alpha,5 alpha-THP) in the brain, which may have anxiolytic effects. The purpose of this experiment was to investigate the effects of olanzapine administration on anxiety behavior and progestin levels. Ovariectomized (ovx) rats (N=33) were administered olanzapine (i.p.: 5.0 or 10.0 mg/kg) or vehicle (saline buffered with acetic acid) and an hour later were tested for motor and anxiety behavior (n=8 per group) or had tissue collected for measurement of progestin concentrations (n=3 per group). Rats that were administered 5.0 or 10.0 mg/kg of olanzapine spent less time freezing in response to shock in the defensive burying task, spent more time on the open arms of the elevated plus-maze, and spent more time in social interaction with a conspecific than did vehicle-administered rats. Olanzapine (5.0 or 10.0 mg/kg, i.p.) significantly increased plasma and produced non-significant increases in whole brain concentrations of progesterone and 3 alpha,5 alpha-THP compared to that seen following vehicle administration. Together, these data are consistent with the hypothesis that olanzapine reduces fear, has anxiolytic effects, and may enhance social interaction in part due to increasing progestin concentrations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727133     DOI: 10.1016/s0306-4530(02)00049-5

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  17 in total

1.  Corticosteroid and neurosteroid dysregulation in an animal model of autism, BTBR mice.

Authors:  Cheryl A Frye; Danielle C Llaneza
Journal:  Physiol Behav       Date:  2010-03-16

2.  Progesterone's effects to reduce anxiety behavior of aged mice do not require actions via intracellular progestin receptors.

Authors:  C A Frye; K Sumida; B C Dudek; J P Harney; J P Lydon; B W O'Malley; D W Pfaff; M E Rhodes
Journal:  Psychopharmacology (Berl)       Date:  2006-03-15       Impact factor: 4.530

3.  Progesterone reduces depressive behavior of young ovariectomized, aged progestin receptor knockout, and aged wild type mice in the tail suspension test.

Authors:  Cheryl A Frye
Journal:  J Psychopharmacol       Date:  2009-12-04       Impact factor: 4.153

4.  Progesterone attenuates depressive behavior of younger and older adult C57/BL6, wildtype, and progesterone receptor knockout mice.

Authors:  Cheryl A Frye
Journal:  Pharmacol Biochem Behav       Date:  2011-06-06       Impact factor: 3.533

5.  An animal model of schizophrenia based on chronic LSD administration: old idea, new results.

Authors:  Danuta Marona-Lewicka; Charles D Nichols; David E Nichols
Journal:  Neuropharmacology       Date:  2011-02-23       Impact factor: 5.250

6.  Effects of olanzapine infusions to the ventral tegmental area on lordosis and midbrain 3alpha,5alpha-THP concentrations in rats.

Authors:  Cheryl Frye; Angela Seliga
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

7.  Estrogen is necessary for 5alpha-pregnan-3alpha-ol-20-one (3alpha,5alpha-THP) infusion to the ventral tegmental area to facilitate social and sexual, but neither exploratory nor affective behavior of ovariectomized rats.

Authors:  C A Frye; J J Paris; M E Rhodes
Journal:  Pharmacol Biochem Behav       Date:  2008-08-23       Impact factor: 3.533

8.  Infusions of bicuculline to the ventral tegmental area attenuates sexual, exploratory, and anti-anxiety behavior of proestrous rats.

Authors:  Cheryl A Frye; Jason J Paris
Journal:  Pharmacol Biochem Behav       Date:  2009-07-01       Impact factor: 3.533

9.  Progesterone reduces hyperactivity of female and male dopamine transporter knockout mice.

Authors:  Cheryl A Frye; Ichiro Sora
Journal:  Behav Brain Res       Date:  2010-01-20       Impact factor: 3.332

Review 10.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.